Abstract: The present invention relates to the compounds 3 -(benzo[d][1,3]dioxol-5-yl)-7-(1-hydroxypropan-2-yl)-1-(1H -indol-3-yl)-6,7-dihydro-3H-oxazol[3,4-a]pyrazine-5,8-dione of formula (I)), and also to pharmaceutically acceptable stereoisomers, salts, solvates, hydrates, prodrugs and esters thereof; the stereoisomers being in their separate individual forms and/or in the forms of racemic mixtures or non-racemic mixtures with diastereomeric excess in any proportions, a pharmaceutical composition comprising at least one of the compounds described; the use of said stereoisomers as an antitumor agent or phosphodiesterase enzyme inhibitor, and the use of said stereoisomers in the treatment of benign prostatic hyperplasia and cancer, more specifically prostate cancer.

Abstract: The present invention describes new pyridopyrimidine derivatives compounds with structure represented by General Formula (I): or pharmaceutically acceptable salts thereof, or their mixtures (in any ratio), a pharmaceutical composition containing them, a method for using the new pyridopyrimidine derivatives compounds as inhibitor of the cyclic nucleotide synthesis or as inhibitor of the cAMP and cGMP synthesis, and their uses in the prophylactic and/or curative treatment of diarrhea, colitis and irritable bowel syndrome.

Abstract: The present invention relates to a dermocosmetic composition comprising natural substances for topical use, to improve the appearance, protection and strengthening of nails as well as assisting in the recovery of nail disorders. Additionally, the present invention also relates to a process for preparing said composition, a method for strengthening of fragile nails, and the use of this composition in the preparation of a topical composition for the treatment of nail disorders.

Abstract: The present invention describes new pyridopyrimidine derivatives compounds with structure represented by General Formula (I): or pharmaceutically acceptable salts thereof, or their mixtures (in any ratio), a pharmaceutical composition containing them, a method for using the new pyridopyrimidine derivatives compounds as inhibitor of the cyclic nucleotide synthesis or as inhibitor of the cAMP and cGMP synthesis, and their uses in the prophylactic and/or curative treatment of diarrhea, colitis and irritable bowel syndrome.

Abstract: The present invention describes cosmetic nanotechnology, comprising polymeric nanoparticles containing oil and UV filter, photoprotective compositions comprising polymeric nanoparticles described herein, methods of prevention of diseases of the skin, and processes for the preparation of the polymeric nanoparticles described herein.

Abstract: The present invention aims to provide a pharmaceutical composition for the treatment of alopecia, said composition comprising polymeric nanoparticles, preferably nanocapsules, containing finasteride, additives and a pharmaceutically acceptable carrier, as well as the use of the nanoparticles for preparing said composition for treating alopecia. The invention further includes an appropriate finasteride nanocapsule preparation process suitable for a composition for topical application for treating alopecia.

Abstract: The present invention relates to a pharmaceutical composition for topical application for the treatment of alopecia, said composition comprising polymeric nanoparticles, preferably nanocapsules containing two active ingredients, finasteride and minoxidil, additives and a pharmaceutically acceptable carrier. The invention further includes a process for the preparation of polymeric nanoparticles, preferably nanocapsules of finasteride and minoxidil, a composition suitable for topical application for the treatment of alopecia, as well as the use of said nanocapsules for the preparation of a pharmaceutical composition.

Abstract: The present invention relates to novel derivatives of 6,7-dihydro-3H-oxazolo[3,4-a]pyrazine-5,8-dione represented by formula (I): and a mixture of these derivatives. The present invention also encompasses the pharmaceutical compositions comprising an effective amount of a said compounds, object of the present invention, as well as to the use of the compounds and/or derivatives as a phosphodiesterase enzyme inhibitor, and the use of the compounds and/or derivatives in the treatment of erectile dysfunction, disorders and/or conditions treatable with relaxation of tissues and disorders treatable with phosphodiesterase inhibitors, more particularly PDE-5 inhibitor. A further objective of the present invention is to provide a medication comprising a therapeutically effective amount of said compound and a method of treating using the said novel compounds.

Abstract: Compositions for regenerating tissue and wound repair, among other applications, are described.

Abstract: The invention refers to pharmaceutical compositions and cosmetic compositions comprising a prophylactic or therapeutically effective quantity of at least one polypeptide substantially identical to Lopap (a lipocalin-related protein with prothrombin activating protease activity). The invention refers to the use of these compositions as modulators of cell death and anti-aging agents.

Abstract: The present invention relates to a nanoparticulated anaesthetic composition for topical use in which at least one local anaesthetic agent is encapsulated in polymeric nanoparticles. The present invention also relates to the use of such polymeric nanoparticles comprising at least one local anaesthetic agent in the preparation of an anaesthetic composition for topical application to the skin or mucosa.

Abstract: A series of derivatives of 6,7-dihydro-3H-oxazolo[3,4-a]pyrazine-5,8-dione, mixtures thereof, their pharmaceutically acceptable salts, which are inhibitors of PDE-5, possessing vasodilatator properties and relaxing effects. In particular, compounds of formula (I), where R1, R2, R3, and R4 are defined herein, processes for the preparation of said compounds, pharmaceutical compositions containing them, as well as uses as inhibitors of the enzyme phosphodiesterase type 5 (PDE-5) in the treatment of the erectile dysfunction and PDE-5 inhibitor treatable disorders.

Abstract: The present invention describes a series of derivatives of 2-(3-methylenedioxy)-benzoyl indol, their mixtures, their pharmaceutically acceptable salts, their enantiomers, pharmaceutical compositions comprising them, processes for preparing them, use in the prophylactic and/or curative treatment of sexual dysfunction. More specifically, the invention describes derivatives (R)-3-((2-(benzo[d][1,3]dioxol-5-carbonyl)-1H-indol-3-yl)methyl)-1-methylpiperazine-2,5-dione, and S)-3-((2-(benzo[d][1,3]dioxol-5-carbonyl)-1H-indol-3-yl)methyl)-1-methylpiperazine-2,5-dione.

Abstract: This invention describes new antifungal compounds that are aralkyl benzyl ethers of the formula (I): wherein: Ar represents aryl, imidazolil, 1,2,4-triazolyl, benzimidazolil; R1, R2, R4 and R5 are independently hydrogen, halogen, C1-6 alkyl; R3 represents halogen, C1-6alkyl or O—R? where R? represents hydrogen or lower alkyl; R6 represents aryl, substituted aryl, trifluoromethyl, trichloromethyl or O—R? where R? represents hydrogen or lower alkyl; being the substituents of the aryl a halogen or a radical tetrazolyl; n and m represent independently an integer between 0 and 5; With the proviso that when Ar is imidazolil, R3 is chlorine, R6 is p-phenyl and R1, R2, R4 and R5 are hydrogen, n must be different from 2. When n and m are not 0 and 1, R3 or R6 can be represented by substituents not necessarily equal.

Abstract: The present invention describes a series of derivatives of 6,7-dihydro-3H-oxazolo[3,4-a]pyrazine-5,8-dione, mixtures thereof, their pharmaceutically acceptable salts, which are inhibitors of PDE-5, possessing vasodilatator properties and relaxing effects. In particular, the derivative (R)-3-(1,3-benzodioxol-5-yl)-1-(1H-indol-3-yl)-7-methyl-6,7-dihydro[1,3]oxazolo[3,4-a]pyrazine-5,8-dione, its enantiomer (S)-3-(1,3-benzodioxol-5-yl)-1-(1H-indol-3-yl)-7-methyl-6,7-dihydro[1,3]oxazolo[3,4-a]pyrazine-5,8-dione. The present invention describes, additionally, processes for the preparation of said compounds, pharmaceutical compositions containing them, thereof, as well as uses as inhibitors of the enzyme phosphodiesterase type 5 (PDE-5) in the treatment of the erectile dysfunction and PDE-5 inhibitor treatable disorders.

Abstract: The present invention describes a series of derivatives of 2-(3-methylenedioxy)-benzoyl indol, their mixtures, their pharmaceutically acceptable salts, their enantiomers, pharmaceutical compositions comprising them, processes for preparing them, use in the prophylactic and/or curative treatment of sexual dysfunction. More specifically, the invention describes derivatives (R)-3-((2-(benzo[d][1,3]dioxol-5-carbonyl)-1H-indol-3-yl)methyl)-1-methylpiperazine-2,5-dione, and S)-3-((2-(benzo[d][1,3]dioxol-5-carbonyl)-1H-indol-3-yl)methyl)-1-methylpiperazine-2,5-dione.

Abstract: The present invention relates to the use of Ang-(1-7) and/or Ang-(1-7) receptor agonist and/or Ang (1-7) analogue in treating/restoring erectile dysfunction.

Abstract: The present invention relates to a nanoparticulated anaesthetic composition for topical use in which at least one local anaesthetic agent is encapsulated in polymeric nanoparticles. The present invention also relates to the use of such polymeric nanoparticles comprising at least one local anaesthetic agent in the preparation of an anaesthetic composition for topical application to the skin or mucosa.

Abstract: The present invention relates to a pharmaceutical composition comprising a combination of active principles. More specifically: a stable pharmaceutical composition comprising a combination of tramadol and ketoprofen. Furthermore, a combination in solid form in which the active principles are vehicled in pharmaceutical forms and/or products that prevent contact between them. Complementarily, the present invention also relates to the combined use of ketoprofen and tramadol in the preparation of an oral medicine useful for relieving pain as well as a method for relieving pain with an oral pharmaceutical composition comprising a combination of tramadol and ketoprofen.